· Published by Health Canada · Official notice
This is duplicated text of a letter from Glaxo SmithKline.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
September 24, 2001
Safety Information for Patients Taking ZYBAN®(bupropion)
GlaxoSmithKline, following discussions with Health Canada, would like to inform consumers about important safety information for Zyban®, a medication used to help people stop smoking and available in Canada since August 1998. Over 1.25 million patients in Canada have been prescribed Zyban. Bupropion hydrochloride, the active ingredient in Zyban, is also available under the name Wellbutrin® SR for use in treating depression. Wellbutrin SR has been available in Canada since May 1998. The important safety information below applies to those patients who are taking bupropion.
Zyban is generally well tolerated. However, as with any medication, adverse reactions are possible when taking Zyban. The most common side effects are dry mouth and difficulty sleeping. These effects are usually mild and temporary. Other side effects that have commonly been reported include nausea, constipation, headache, shakiness and altered taste. You may also experience some side effects while taking Zyban, which are also effects associated with stopping smoking. These include having difficulty concentrating, becoming dizzy, confused, anxious, fidgety, irritable, depressed, or rarely, you may have a very marked mood change.
High blood pressure, in some cases severe, has been reported in patients taking Zyban alone and in combination with nicotine replacement therapy (for example, a nicotine patch), used to help patients stop smoking. Tell your doctor if you are using, or plan to use, nicotine replacement therapy. Infrequently, you may experience chest pain, possibly heart related, an increase in heart rate or, rarely, you may faint during treatment with Zyban.
There is a chance that approximately one out of 1000 patients taking Zyban may have a seizure. This risk may increase with some medical conditions or if you are taking certain medications, so it is important to inform your doctor of all the medications you are taking and any medical conditions you may have. Be certain to also discuss your use of alcohol with your doctor prior to using Zyban.
In order to reduce the risk of a seizure, you should not take Zyban if:
Other medical conditions that may increase your risk for seizure include: history of seizures, serious head injury, diabetes that is treated with insulin or other medications, and some liver problems. You can reduce the chance of experiencing a seizure by following your doctor's directions as to how to take Zyban. You should not take more than 150 mg (1 pill) at a time. When you are taking two daily doses of 150 mg each (2 pills per day), doses should be taken at least eight hours apart. If you experience a seizure while taking Zyban, go to a doctor or hospital immediately, and do not take any more of the drug.
You should also not take Zyban if you have taken a monoamine oxidase (MAO) inhibitor or thioridazine (Mellaril) within the past 14 days, or if you are allergic to any of the ingredients in Zyban tablets. It is important to be aware of the signs and symptoms of an allergic reaction, which may include skin rash, difficulty breathing, itching, hives, chest pain, and swelling of the mouth or face. If you experience these symptoms, stop taking Zyban immediately and contact your doctor.
Zyban may affect other medicines you are taking. Sometimes the dose of another medicine may need to be adjusted when Zyban is started. You should make sure your doctor knows about all prescription and over-the-counter medicines you are taking or plan to take while taking Zyban.
Other side effects are also possible with Zyban. If you are concerned about any adverse reaction when taking Zyban or Wellbutrin SR, please contact your doctor.
GlaxoSmithKline has recently provided physicians with a similar update about safety information to help ensure that physicians are prescribing the medication optimally. This information may be obtained on the Canadian website of GlaxoSmithKline (http://www.gsk.ca) or on the website of the Therapeutic Products Directorate of Health Canada (Advisories Issued by Industry).
Zyban® is a registered trademark, used under license by GlaxoSmithKline Inc.
Wellbutrin® SR is a registered trademark, GlaxoSmithKline Inc.
Any suspected adverse reactions can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Bureau of Licensed Product Assessment
Therapeutic Products Directorate
HEALTH CANADA
Address Locator: 0201C2
OTTAWA, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals and Specialties, or on the TPD website, along with the ADR Guidelines.